anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Inactivated antigens have only been used in avian medicine in parenterally administered vaccines. The only mucosally administered vaccines have been live, modified live, or attenuated vaccines. However, live vaccines have several disadvantages, including the risk of causing disease. Disclosed embodiments concern a composition comprising inactivated bacterial and/or viral antigens that is formulated for mucosal administration to an avian, and a method of using the composition. In certain embodiments, the composition comprises inactivated Clostridium perfringens type A antigens, and/or Salmonella spp. antigens, such as antigens from Salmonella kentucky, Salmonella typhimurium, and/or Salmonella enteriditis, or E. coli antigens. The composition may comprise a polyacrylic acid adjuvant. The composition may be administered to an avian in ovo, during the first 14 days after hatching, or after the first 14 days.
BACKGROUND: DNA methylation-derived epigenetic clocks and frailty are well-established biological age measures capturing different aging processes. However, whether they are dynamically linked to each other across chronological age remains poorly understood.
METHODS: This analysis included 1 309 repeated measurements in 524 individuals aged 50-90 years from the Swedish Adoption/Twin Study of Aging. Frailty was measured using a validated 42-item frailty index (FI). Five epigenetic clocks were calculated, including 4 principal component (PC)-based clocks trained on chronological age (PCHorvathAge and PCHannumAge) and aging-related physiological conditions (PCPhenoAge and PCGrimAge), and a pace of aging clock (DunedinPACE). Using dual change score models, we examined the dynamic, bidirectional associations between each of the epigenetic clocks and the FI over age to test for potential causal associations.
RESULTS: The FI exhibited a nonlinear, accelerated increase across the older adulthood, whereas the epigenetic clocks mostly increased linearly with age. For PCHorvathAge, PCHannumAge, PCPhenoAge, and PCGrimAge, their associations with the FI were primarily due to correlated levels at age 50 but with no evidence of a dynamic longitudinal association. In contrast, we observed a unidirectional association between DunedinPACE and the FI, where a higher DunedinPACE predicted a subsequent increase in the FI, but not vice versa.
CONCLUSIONS: Our results highlight a temporal order between epigenetic aging and frailty such that changes in DunedinPACE precede changes in the FI. This potentially suggests that the pace of aging clock can be used as an early marker of the overall physiological decline at system level.
PROBLEM TO BE SOLVED: To obtain a hair tonic having hair growth period extension effect, namely, capable of maintaining and extending the hair growth period in the hair cycle through promoting hair growth by including a sugar glyceride as active ingredient. SOLUTION: This hair tonic is obtained by including pref. 0.01-10.0 wt.% of a sugar glyceride pref. of the formula (R1 is a sugar residue; R2 and R3 are each H or a saturated fatty acid residue or the like) as active ingredient; wherein the sugar is pref. galactose, glucose or fructose. The formulation of this hair tonic is e.g. a liquid, milky lotion, ointment, being in the form of tonic, hair cream moose, shampoo, etc. Furthermore, this hair tonic may be formulated with a surfactant (e.g. higher saturated fatty acid), moisturizer (e.g. glycerol), thickening agent (e.g. quince mucous matter), antiseptic (e.g. salicylic acid), vasodilator (e.g. nicotinamide), etc.
The present invention provides anti-BLyS antibodies, pharmaceutical compositions thereof, and uses thereof. The anti-BLyS antibody or the antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of LCDR1, LCDR2 and LCDR3 are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and the amino acid sequences of HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The anti-BLyS antibody or the antigen-binding fragment thereof of the present invention has excellent binding ability to the human BLyS protein and ability to competitively inhibit the binding of human BLyS to its receptor, human BR 3. The pharmaceutical composition of the present invention is a highly stable pharmaceutical composition comprising an anti-BLyS antibody and a buffer, and may further comprise at least one stabilizer and optionally a surfactant.
This invention demonstrates that the PEG10 protein suppresses apoptosis and promotes cancer cell growth. Furthermore, PEG10 protein was found to be degraded through interaction with SIAH1 protein. This invention provides methods of regulating cell growth and cell death using the PEG10 protein. Furthermore, the present invention provides methods of screening for novel anticancer agents which use the PEG10 protein. The screening of this invention enables development of pharmaceutical agents that induce apoptosis and suppress cell growth by specifically targeting cancer cells. In particular, since the PEG10 protein is specifically expressed in hepatoma cells, it is an ideal target molecule for diagnosis and treatment of hepatoma.
FIELD: veterinary science, fur farming. SUBSTANCE: polar fox offspring aged 3 months to slaughtering for the purpose to obtain polar fox skins are transferred to such a feeding diet that has one emptying day per a week at 90-85% energetic nutrition level against already existed norms. Diet during the period since June to October is supplemented with antioxidants as agidole at 2-40 mg/kg live body weight daily or phenoxane at the dose of 1.5-5 mg/kg. The method enables to increase polar fox skin area by 1.7-4.7% at high quality values, decrease fodder expenses by 8.2-12.2% and introduce one general day-off for the personnel in fur-breeding farms. EFFECT: higher efficiency. 1 tbl
BACKGROUND: Chronic non-cancer pain may affect up to 51% of the general population. Pharmacist interventions have shown promise in enhancing patient safety and outcomes. However, our understanding of the scope of pharmacists' interventions remains incomplete.
AIM: Our goal was to characterise pharmacists' interventions for the management of chronic non-cancer pain.
METHOD: Medline, Embase, PsycINFO via Ovid, CINAHL via EBSCO databases and the Cochrane Library were systematically searched. Abstracts and full texts were independently screened by two reviewers. Data were extracted by one reviewer, and validated by the second. Outcomes of studies were charted using the dimensions of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT).
RESULTS: Forty-eight reports were included. Interventions ensuring appropriate drug prescription occurred in 37 (79%) studies. Patient education and healthcare professional education were reported in 28 (60%) and 5 (11%) studies, respectively. Therapy monitoring occurred in 17 (36%) studies. Interventions regularly involved interprofessional collaboration. A median of 75% of reported outcome domains improved due to pharmacist interventions, especially patient disposition (adherence), medication safety and satisfaction with therapy.
CONCLUSION: Pharmacists' interventions enhanced the management of chronic non-cancer pain. Underreported outcome domains and interventions, such as medication management, merit further investigation.
The efficacy of Fomepizole in the treatment of ethylene glycol and methanol intoxication was studied in two prospective, U.S. clinical trials without concomitant control groups. Fourteen of 16 patients in the ethylene glycol trial and 7 of 11 patients in the methanol trial underwent hemodialysis because of severe intoxication (see DOSAGE AND ADMINISTRATION). All patients received Fomepizole shortly after admission.

The results of these two studies provide evidence that fomepizole blocks ethylene glycol and methanol metabolism mediated by alcohol dehydrogenase in the clinical setting. In both studies, plasma concentrations of toxic metabolites of ethylene glycol and methanol failed to rise in the initial phases of treatment. The relationship to fomepizole therapy, however, was confounded by hemodialysis and significant blood ethanol concentrations in many of the patients. Nevertheless, in the post-dialysis period(s), when ethanol concentrations were insignificant and the concentrations of ethylene glycol or methanol were > 20 mg/dL, the administration of fomepizole alone blocked any rise in glycolate or formate concentrations, respectively.

In a separate French trial, 5 patients presented with ethylene glycol concentrations ranging from 46.5 to 345 mg/dL, insignificant ethanol blood concentrations, and normal renal function. These patients were treated with fomepizole alone without hemodialysis, and none developed signs of renal injury.
VSL#3 is classified as a medical food that is specially formulated and processed to provide a precise mixture of 8 strains of bacterial species with potential synergistic relationships. These strains include Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus.
1. Technical Result Increase in treatment efficiency and widening of assortment of ointments for treatment of skin diseases.         2. Essence An ointment comprises active ingredients – mercury amidochloride, salicylic acid, resorcin, salol, Streptocid, Levomycetin, carrier and base. The ointment is used for treatment of neurodermite, various skin eruptions, blackheads, freckles, spots, acnerosacea and dermodex.          3. Field of Application Medicine.
This is a 13-week, open-label (all people know the identity of the intervention), single-arm (one group of patients), multicenter, prospective, interventional study in Chinese patients. In a prospective, interventional study, the patients identified receive a treatment during the course of the research study and are followed forward in time for the outcome of the study. In China, there is still insufficient information about effectiveness, tolerability, and dosage strategy for directly switching from previous oral antipsychotics (drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders) in patients with acute symptoms. Acute symptoms are quick and severe form of illness in its early stage. In addition, there is also lack of information about bridging acute phase to long-term treatment. In this study, patients with multiple types of acute schizophrenia will be recruited and will receive Sustenna (paliperidone palmitate) treatments for 13 weeks. After the acute treatment, the patients will continue to receive the prescribed medication and will be followed up for an additional 52 weeks to assess the outcomes related to long-term treatment.
Atherosclerosis (AS) is a chronic inflammatory arterial disease, in which abnormal lipid metabolism and foam cell formation play key roles. Histamine is a vital biogenic amine catalyzed by histidine decarboxylase (HDC) from L-histidine. Histamine H1 receptor (H1R) antagonist is a commonly encountered anti-allergic agent in the clinic. However, the role and mechanism of H1R in atherosclerosis have not been fully elucidated. Here, we explored the effect of H1R on atherosclerosis using Apolipoprotein E-knockout (ApoE-/-) mice with astemizole (AST, a long-acting H1R antagonist) treatment. The results showed that AST increased atherosclerotic plaque area and hepatic lipid accumulation in mice. The result of microarray study identified a significant change of endothelial lipase (LIPG) in CD11b+ myeloid cells derived from HDC-knockout (HDC-/-) mice compared to WT mice. Blocking H1R promoted the formation of foam cells from bone marrow-derived macrophages (BMDMs) of mice by up-regulating p38 mitogen-activated protein kinase (p38 MAPK) and LIPG signaling pathway. Taken together, these findings demonstrate that blocking H1R signal aggravates atherosclerosis by promoting abnormal lipid metabolism and macrophage-derived foam cell formation via p38 MAPK-LIPG signaling pathway. KEY MESSAGES: Blocking H1R signal with AST aggravated atherosclerosis and increased hepatic lipid accumulation in high-fat diet (HFD)-fed ApoE-/- mice. Blocking H1R signal promoted macrophage-derived foam cell formation via p38 MAPK-LIPG signaling pathway.
The invention belongs to the technical field of drug transport and particularly relates to a hepatic stellate cell-targeted gene drug transport vector and a preparation method and application thereof. According to the method, by means of coupling retinol molecules to a polyethyleneimine vector, the gene drug transport vector is used for treating hepatic fibrosis and liver cirrhosis by means of an active targeting function to the hepatic stellate cell. A positive ion material polyethyleneimine in the vector wraps the gene drug by means of non-covalent electrostatic interaction, so that the drug is easier to release out. The retinol in the vector endows the vector with hepatic stellate cell targeting characteristic, so that the utilization ratio of the drug is improved, and the toxic and side effects are reduced. The vector entering blood for circulation can be combined with albumin, so that the circulation time of the vector is prolonged. The invention provides the novel effective gene drug transport vector for preventing hepatic fibrosis and liver cirrhosis for common chronic progressive liver diseases such as hepatic fibrosis, liver cirrhosis and the like.
A composition for in vitro and in vivo transfection of vertebrate male germ cells comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral component, which is internalized by cells along with the transgene and which enhances gene transfer through the cytoplasm to the nucleus of the male germ cell. A method of genetically altering a vertebrate male germ cell in vivo employs a lentiviral-derived vector. A method of substantially depopulating a vertebrate testis employs a combination of a dose of an alkylating agent, such as busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid, and a dose of gamma radiation. A pharmaceutical preparation and a transfer kit utilize the composition. A method for introducing a polynucleotide into vertebrate male germ cells comprises the administration of the composition to a vertebrate. A method for isolating or selecting transfected cells utilizes a reporter gene, and a method for administering transfected male germ cells utilizes male germ cells which have been transfected in vitro.
Ten healthy habitual runners (\> 50km running per week) between 18-60 years of age participated in this double blind randomized control trial. Each subject presented to the exercise lab on four separate occasions. Trial 1 was a familiarization trial to determine each subject's maximal aerobic capacity and peak treadmill running speak (VO2 Peak test). Trials 2, 3 and 4 utilized the same exact protocol, differing only in pharmacological intervention. In a randomized, double-blind order (both participant and investigator blinded to the intervention), either a placebo pill, the V2 receptor antagonist tolvaptan (Samsca™, 30mg tablet), or the V2 receptor agonist desmopressin (DDAVP™, 0.2mg tablet) was ingested along with the CorTemp™ Core Temperature Sensor two hours before commencement of the Exercise Trial with 240mL of bottled water. The exercise protocol consisted of 60 minutes of treadmill running at 60% of peak speed (steady-state) followed by a performance test (the VO2 Peak test). Blood, saliva and urine, were collected before the exercise trial (baseline) and again after both the steady-state run and performance runs. Sweat was obtained from sweat patches after both the steady-state and performance runs. Core temperature, fluid intake, performance time, body weight, thirst and sodium palatability ratings were also assessed. Free access to water was allowed during the trial and all urine produced during the trial was measured and collected. The main outcome measure was sweat sodium concentration.
BACKGROUND: Dystonia is one of the most common movement disorders. To date, the genetic causes of dystonia in populations of European descent have been extensively studied. However, other populations, particularly those from the Middle East, have not been adequately studied. The purpose of this study is to discover the genetic basis of dystonia in a clinically and genetically well-characterised dystonia cohort from Turkey, which harbours poorly studied populations.
METHODS: Exome sequencing analysis was performed in 42 Turkish dystonia families. Using co-expression network (CEN) analysis, identified candidate genes were interrogated for the networks including known dystonia-associated genes and genes further associated with the protein-protein interaction, animal model-based characteristics and clinical findings.
RESULTS: We identified potentially disease-causing variants in the established dystonia genes (PRKRA, SGCE, KMT2B, SLC2A1, GCH1, THAP1, HPCA, TSPOAP1, AOPEP; n=11 families (26%)), in the uncommon forms of dystonia-associated genes (PCCB, CACNA1A, ALDH5A1, PRKN; n=4 families (10%)) and in the candidate genes prioritised based on the pathogenicity of the variants and CEN-based analyses (n=11 families (21%)). The diagnostic yield was found to be 36%. Several pathways and gene ontologies implicated in immune system, transcription, metabolic pathways, endosomal-lysosomal and neurodevelopmental mechanisms were over-represented in our CEN analysis.
CONCLUSIONS: Here, using a structured approach, we have characterised a clinically and genetically well-defined dystonia cohort from Turkey, where dystonia has not been widely studied, and provided an uncovered genetic basis, which will facilitate diagnostic dystonia research.
The present invention relates to TGF-beta receptor II isoforms, fusion peptides, methods of treatment and in vitro methods. The isoform of tgfβ receptor II comprises a sequence of about 80 amino acids and lacks a transmembrane domain. The isoform comprises the amino acid sequence shown in SEQ ID No. 12. The isoform may have the sequence shown as SEQ ID No.2 or a sequence having at least 85% sequence identity to the sequence shown as SEQ ID No. 2. The present invention provides fusion peptides comprising an isoform of the tgfβii receptor fused to a ligand, wherein a vector comprising the fusion peptide is used to treat cancer and/or liver fibrosis. The present invention provides antibodies that bind to soluble isoforms of the TGF-beta II receptor. The antibody binds to the amino acid sequence shown in SEQ ID No.12 and is useful in vitro methods.
At enrolment, subjects were stratified into two age strata (18 to 60 years, over 60 years). Total duration of the study is eight weeks, which include two weeks for enrolment and 6 weeks for study participation. Vaccinations were to be administered on day 1 and day 22. Blood samples were collected at day 1 (baseline, before the first vaccination), at day 22 (before the second vaccination), at day 29 (one week after the second vaccination) and at day 43 (three weeks after the second vaccination). Sera were tested by Hemagglutination Inhibition (HI) and Microneutralization (MN) assays. Safety was assessed until 3 weeks after the first and second vaccination.
This study will evaluate the safety of three doses of BSYX-A110 in adults before initiating studies in the target population of low birth weight infants. This will be an open label, dose-ranging study of BSYX-A110 in 12 adults. The dose levels to be evaluated are 3, 10 and 20 mg/kg. Each dose level will enroll 4 adult volunteers who will receive one dose of BSYX-A110 intravenously. The primary endpoint of this study is safety and tolerability. The secondary endpoints include the pharmacokinetics of the rise in anti-LTA antibody and opsonic activity against S. epidermidis.
FIELD: medicine. ^ SUBSTANCE: what is offered is a human OX40L antibody containing a light chain and a heavy chain each of which contains respectively three CDRs of the light chain and three CDRs of the heavy chain. There are described: a coding polynucleotide, and also an expression vector and a host cell including coding polynucleotide. There are disclosed: a method of producing and a method of treating with using the antibody. ^ EFFECT: use of the invention can find further application in therapy of the OX40L mediated immune disorders. ^ 28 cl, 8 dwg, 1 tbl, 7 ex
In Stage 1, up to 5 Type II subjects will receive 1.5E13 vg/kg of the gene transfer agent, and two Type II subjects will receive 4.5E13 vg/kg of the gene transfer agent. In Stage 1, up to 3 Type I subjects will receive 1.5E13 of the gene transfer agent (Cohort 1) and then up to 3 subjects will receive 4.5E13 of the gene transfer agent (Cohort 2).
Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks, including two components: family counseling (30 min) and family conversation training (30 min). Family counseling aims to increase the PD families' knowledge about PD in general and to identify goals and potential solutions to problems which cause emotional turmoil. Family conversation training which aims to increase the PD families' knowledge about PD-related communication problems and to raise awareness of their communication patterns, and to support the development of functional strategies. All activities will remotely occur (using Zoom).
INTRODUCTION: Epilepsy is the most common neurological disorder among humans after headaches. According to the World Health Organization, approximately 50-65 million individuals were diagnosed with epilepsy throughout the world, and around two million new cases of epilepsy are added to this figure every year.
METHODS: Designed as descriptive and cross-sectional research, this study was performed on 132 elementary school teachers. Training on epilepsy and epileptic seizure was given to teachers. The pretest and posttest research data were collected with the face-to-face interview method. In this process, the epilepsy knowledge scale was used as well as a survey form that had questions designed to find out about teachers' personal characteristics. The Statistical Package for Social Science 25.0 was utilized in the statistical analysis of research data. In the research, the statistical significance was identified if the p-value was below.05 (p < .05).
RESULTS: Of all teachers participating in the study, 59.1% were female, 90.2% were married, and 47.7% witnessed an epilepsy seizure before. The mean of teachers' pretest epilepsy knowledge scores was 8.43 ± 4.31 points before the training while the mean of their posttest epilepsy knowledge scores was 12.65 ± 2.48 points after the training. The difference between the means of pretest and posttest scores was statistically significant (p = .000). After the training, there was a statistically significant increase in means of scores obtained by teachers from each item of the epilepsy knowledge scale (p < .05).
CONCLUSIONS: As there was a statistically significant improvement in levels of teachers' knowledge about both epilepsy and epileptic seizure after the training, it is recommended that the training about the approach to epilepsy and epileptic seizure be given to all teachers, and additionally, including these topics in the course curricula of universities is recommended.